Investors: Press Releases

Press Releases

January 18, 2021
Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer
January 4, 2021
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
December 7, 2020
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
November 4, 2020
NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting
October 27, 2020
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
October 6, 2020
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
September 23, 2020
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
June 1, 2020
NexImmune to Present at the Jefferies Virtual Healthcare Conference
January 8, 2020
NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
December 19, 2019
Neximmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
Displaying 51 - 60 of 71